CA2856309C - Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors - Google Patents
Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors Download PDFInfo
- Publication number
- CA2856309C CA2856309C CA2856309A CA2856309A CA2856309C CA 2856309 C CA2856309 C CA 2856309C CA 2856309 A CA2856309 A CA 2856309A CA 2856309 A CA2856309 A CA 2856309A CA 2856309 C CA2856309 C CA 2856309C
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- aryl
- cycloalkyl
- heterocyclyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2011/085148 WO2013097225A1 (en) | 2011-12-31 | 2011-12-31 | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2856309A1 CA2856309A1 (en) | 2013-07-04 |
| CA2856309C true CA2856309C (en) | 2016-06-07 |
Family
ID=48696280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2856309A Active CA2856309C (en) | 2011-12-31 | 2011-12-31 | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US9260440B2 (instruction) |
| EP (2) | EP2797921B1 (instruction) |
| JP (1) | JP6034877B2 (instruction) |
| KR (1) | KR101716012B1 (instruction) |
| CN (2) | CN106220635B (instruction) |
| AU (1) | AU2011384858B2 (instruction) |
| BR (1) | BR112014012628B8 (instruction) |
| CA (1) | CA2856309C (instruction) |
| CY (1) | CY1119804T1 (instruction) |
| DK (1) | DK2797921T3 (instruction) |
| EA (1) | EA027533B1 (instruction) |
| ES (1) | ES2645814T3 (instruction) |
| HR (1) | HRP20171883T1 (instruction) |
| HU (1) | HUE035153T2 (instruction) |
| IL (1) | IL233365A (instruction) |
| IN (1) | IN2014DN06169A (instruction) |
| LT (1) | LT2797921T (instruction) |
| ME (1) | ME02855B (instruction) |
| MX (1) | MX353578B (instruction) |
| NO (1) | NO2797921T3 (instruction) |
| NZ (1) | NZ624063A (instruction) |
| PL (1) | PL2797921T3 (instruction) |
| PT (1) | PT2797921T (instruction) |
| RS (1) | RS56616B1 (instruction) |
| SG (1) | SG11201401726VA (instruction) |
| SI (1) | SI2797921T1 (instruction) |
| SM (1) | SMT201700543T1 (instruction) |
| WO (1) | WO2013097225A1 (instruction) |
| ZA (1) | ZA201405560B (instruction) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6034877B2 (ja) | 2011-12-31 | 2016-11-30 | ベイジーン リミテッド | Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン |
| MX346147B (es) | 2012-03-07 | 2017-03-09 | Inst Of Cancer Research: Royal Cancer Hospital (The) | Compuestos de 3-aril-5-substituido-isoquinolin-1-ona y su uso terapeutico. |
| JP6456392B2 (ja) | 2013-09-11 | 2019-01-23 | インスティチュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル | ３−アリール−５−置換イソキノリン−１−オン化合物及びその治療的使用 |
| US10457680B2 (en) * | 2015-08-25 | 2019-10-29 | Beigene, Ltd. | Process for preparing a PARP inhibitor, crystalline forms, and uses thereof |
| AU2017242027B2 (en) * | 2016-04-01 | 2020-10-08 | Recurium Ip Holdings, Llc | Estrogen receptor modulators |
| US11202782B2 (en) | 2016-09-27 | 2021-12-21 | Beigene, Ltd. | Treatment cancers using a combination comprising PARP inhibitors |
| WO2018157794A1 (en) * | 2017-02-28 | 2018-09-07 | Beigene, Ltd. | Crystalline forms of salts of fused tera or penta-cyclic dihydrodiazepinocarazolones, and uses thereof |
| CN106883232B (zh) * | 2017-03-31 | 2019-01-22 | 苏州康润医药有限公司 | 一种氮杂非那烯-3-酮的衍生物及其制备方法与应用 |
| US20200155567A1 (en) * | 2017-07-17 | 2020-05-21 | Beigene, Ltd. | Treatment of cancers using a combination comprising parp inhibitors, temozolomide and/or radiation therapy |
| AU2019275722A1 (en) * | 2018-06-01 | 2020-11-12 | Beigene, Ltd. | Maintenance therapy of a PARP inhibitor in treating gastric cancer |
| CN111171031B (zh) * | 2019-05-10 | 2021-04-09 | 百济神州(苏州)生物科技有限公司 | 一种含parp抑制剂倍半水合物产物的制备方法 |
| CN111171002B (zh) * | 2019-05-16 | 2021-04-06 | 百济神州(苏州)生物科技有限公司 | 一种parp抑制剂中间体的制备方法 |
| JP2022534093A (ja) * | 2019-05-31 | 2022-07-27 | ベイジーン リミテッド | Ｐａｒｐ阻害剤ペレット製剤及びその調製方法 |
| BR112022002138A2 (pt) | 2019-08-06 | 2022-04-19 | Recurium Ip Holdings Llc | Moduladores do receptor de estrogênio para tratamento de mutantes |
| WO2021046014A1 (en) | 2019-09-03 | 2021-03-11 | Teva Czech Industries S.R.O | Solid state forms of pamiparib and process for preparation thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE445326B (sv) | 1983-04-05 | 1986-06-16 | Malmstroem Anders E H | Sett och anordning for forhindrande av veggturbulens |
| US6799298B2 (en) | 1998-03-11 | 2004-09-28 | Overture Services, Inc. | Technique for locating an item of interest within a stored representation of data |
| DE60009033T2 (de) | 1999-01-11 | 2004-08-05 | Agouron Pharmaceuticals, Inc., La Jolla | Tricyclische inhibitoren von poly(adp-ribose) polymerasen |
| EP1339402B1 (en) * | 2000-12-01 | 2010-08-25 | Eisai Inc. | Azaphenanthridone derivatives and their use as parp inhibitors |
| US6423705B1 (en) | 2001-01-25 | 2002-07-23 | Pfizer Inc. | Combination therapy |
| US6906096B2 (en) | 2002-06-28 | 2005-06-14 | Irm Llc | 4,7-Disubstituted indoles and methods of making |
| CN1759118B (zh) * | 2003-01-09 | 2010-12-08 | 美国辉瑞有限公司 | 作为激酶抑制剂的二氮杂*并吲哚衍生物 |
| ES2396334T3 (es) | 2003-05-28 | 2013-02-20 | Eisai Inc. | Compuestos, métodos y composiciones farmacéuticas para la inhibición de PARP |
| WO2007113647A1 (en) | 2006-04-04 | 2007-10-11 | Pfizer Products Inc. | Polymorphic forms of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4υl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide |
| CN101415417A (zh) | 2006-04-04 | 2009-04-22 | 辉瑞产品公司 | (2r,z)-2-氨基-2-环己基-n-(5-(1-甲基-1h-吡唑-4-基)-1-氧代-2,6-二氢-1h-[1,2]二氮杂卓并[4,5,6-cd]吲哚-8-基)乙酰胺的组合疗法 |
| JP5758630B2 (ja) | 2007-11-15 | 2015-08-05 | エンメエッセディ・イタリア・エッセ・エッレ・エッレ | Ｐａｒｐ阻害剤としてのピリダジノン誘導体 |
| CN103896942A (zh) | 2008-08-06 | 2014-07-02 | 生物马林药物股份有限公司 | 聚(adp-核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂 |
| WO2011130661A1 (en) | 2010-04-16 | 2011-10-20 | Biomarin Pharmaceutical Inc. | Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp) |
| JP6034877B2 (ja) | 2011-12-31 | 2016-11-30 | ベイジーン リミテッド | Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン |
| AU2013400609B9 (en) | 2013-09-13 | 2020-03-05 | Beone Medicines I Gmbh | Anti-PD1 antibodies and their use as therapeutics and diagnostics |
| CN110156892B (zh) | 2014-07-03 | 2023-05-16 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| US9637488B2 (en) | 2015-01-29 | 2017-05-02 | Fuqiang Ruan | Heterocyclic compounds as inhibitors of class I PI3KS |
| US10457680B2 (en) | 2015-08-25 | 2019-10-29 | Beigene, Ltd. | Process for preparing a PARP inhibitor, crystalline forms, and uses thereof |
| US11202782B2 (en) | 2016-09-27 | 2021-12-21 | Beigene, Ltd. | Treatment cancers using a combination comprising PARP inhibitors |
| WO2018157794A1 (en) | 2017-02-28 | 2018-09-07 | Beigene, Ltd. | Crystalline forms of salts of fused tera or penta-cyclic dihydrodiazepinocarazolones, and uses thereof |
| US20200155567A1 (en) | 2017-07-17 | 2020-05-21 | Beigene, Ltd. | Treatment of cancers using a combination comprising parp inhibitors, temozolomide and/or radiation therapy |
-
2011
- 2011-12-31 JP JP2014549295A patent/JP6034877B2/ja not_active Expired - Fee Related
- 2011-12-31 KR KR1020147018104A patent/KR101716012B1/ko active Active
- 2011-12-31 IN IN6169DEN2014 patent/IN2014DN06169A/en unknown
- 2011-12-31 MX MX2014007840A patent/MX353578B/es active IP Right Grant
- 2011-12-31 AU AU2011384858A patent/AU2011384858B2/en not_active Ceased
- 2011-12-31 PL PL11878508T patent/PL2797921T3/pl unknown
- 2011-12-31 WO PCT/CN2011/085148 patent/WO2013097225A1/en not_active Ceased
- 2011-12-31 SG SG11201401726VA patent/SG11201401726VA/en unknown
- 2011-12-31 LT LTEP11878508.8T patent/LT2797921T/lt unknown
- 2011-12-31 DK DK11878508.8T patent/DK2797921T3/en active
- 2011-12-31 ES ES11878508.8T patent/ES2645814T3/es active Active
- 2011-12-31 HR HRP20171883TT patent/HRP20171883T1/hr unknown
- 2011-12-31 EP EP11878508.8A patent/EP2797921B1/en active Active
- 2011-12-31 RS RS20171228A patent/RS56616B1/sr unknown
- 2011-12-31 SI SI201131351T patent/SI2797921T1/en unknown
- 2011-12-31 US US14/369,374 patent/US9260440B2/en active Active
- 2011-12-31 ME MEP-2017-278A patent/ME02855B/me unknown
- 2011-12-31 BR BR112014012628A patent/BR112014012628B8/pt not_active IP Right Cessation
- 2011-12-31 CN CN201610603192.4A patent/CN106220635B/zh active Active
- 2011-12-31 EP EP17183473.2A patent/EP3315500B1/en active Active
- 2011-12-31 PT PT118785088T patent/PT2797921T/pt unknown
- 2011-12-31 CA CA2856309A patent/CA2856309C/en active Active
- 2011-12-31 NZ NZ624063A patent/NZ624063A/en not_active IP Right Cessation
- 2011-12-31 SM SM20170543T patent/SMT201700543T1/it unknown
- 2011-12-31 EA EA201491303A patent/EA027533B1/ru not_active IP Right Cessation
- 2011-12-31 NO NO11878508A patent/NO2797921T3/no unknown
- 2011-12-31 CN CN201180072418.8A patent/CN103703004B/zh active Active
- 2011-12-31 HU HUE11878508A patent/HUE035153T2/en unknown
-
2014
- 2014-06-25 IL IL233365A patent/IL233365A/en active IP Right Grant
- 2014-07-28 ZA ZA2014/05560A patent/ZA201405560B/en unknown
-
2016
- 2016-01-05 US US14/988,484 patent/US9617273B2/en not_active Expired - Fee Related
-
2017
- 2017-04-05 US US15/479,958 patent/US10112952B2/en active Active
- 2017-11-16 CY CY20171101198T patent/CY1119804T1/el unknown
-
2018
- 2018-09-19 US US16/135,512 patent/US10501467B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2856309C (en) | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors | |
| US11142528B2 (en) | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators | |
| CA2860340C (en) | Fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors | |
| HK1192233B (en) | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140520 |